C M J Matyanga1, K C Takarinda2, P Owiti3, T Mutasa-Apollo4, O Mugurungi4, L Buruwe1, A J Reid5. 1. Pharmaceutical Technology Department, Harare Institute of Technology, Harare, Zimbabwe. 2. AIDS and TB Department, Ministry of Health and Child Care, Harare, Zimbabwe ; International Union Against Tuberculosis and Lung Disease, Paris, France. 3. Academic Model Providing Access to Healthcare (AMPATH), Eldoret, Kenya. 4. AIDS and TB Department, Ministry of Health and Child Care, Harare, Zimbabwe. 5. Medical Department, Médecins Sans Frontières, Operational Centre Brussels, MSF-Luxembourg, Luxembourg.
Abstract
SETTING: A non-governmental organisation-supported clinic offering health services including antiretroviral therapy (ART). OBJECTIVE: To compare ART retention between younger (age 10-14 years) vs. older (age 15-19 years) adolescents and younger (age 20-29 years) vs. older (age ⩾30 years) adults and determine adolescent- and adult-specific attrition-associated factors among those initiated on ART between 2010 and 2011. DESIGN: Retrospective cohort study. RESULTS: Of 110 (7%) adolescents and 1484 (93%) adults included in the study, no differences in retention were observed between younger vs. older adolescents at 6, 12 and 24 months. More younger adolescents were initiated with body mass index <16 kg/m(2) compared with older adolescents (64% vs. 47%; P = 0.04). There were more females (74% vs. 52%, P < 0.001) and fewer patients initiating ART with CD4 count ⩽350 cells/mm(3) (77% vs. 81%, P = 0.007) among younger vs. older adults. Younger adults demonstrated more attrition than older adults at all time-points. No attrition risk factors were observed among adolescents. Attrition-associated factors among adults included being younger, having a lower CD4 count and advanced human immunodeficiency virus disease at initiation, and initiation on a stavudine-based regimen. CONCLUSION: Younger adults demonstrated greater attrition and may require more attention. We were unable to demonstrate differences in attrition among younger vs. older adolescents. Loss to follow-up was the main reason for attrition across all age groups. Overall, earlier presentation for ART care appears important for improved ART retention among adults.
SETTING: A non-governmental organisation-supported clinic offering health services including antiretroviral therapy (ART). OBJECTIVE: To compare ART retention between younger (age 10-14 years) vs. older (age 15-19 years) adolescents and younger (age 20-29 years) vs. older (age ⩾30 years) adults and determine adolescent- and adult-specific attrition-associated factors among those initiated on ART between 2010 and 2011. DESIGN: Retrospective cohort study. RESULTS: Of 110 (7%) adolescents and 1484 (93%) adults included in the study, no differences in retention were observed between younger vs. older adolescents at 6, 12 and 24 months. More younger adolescents were initiated with body mass index <16 kg/m(2) compared with older adolescents (64% vs. 47%; P = 0.04). There were more females (74% vs. 52%, P < 0.001) and fewer patients initiating ART with CD4 count ⩽350 cells/mm(3) (77% vs. 81%, P = 0.007) among younger vs. older adults. Younger adults demonstrated more attrition than older adults at all time-points. No attrition risk factors were observed among adolescents. Attrition-associated factors among adults included being younger, having a lower CD4 count and advanced human immunodeficiency virus disease at initiation, and initiation on a stavudine-based regimen. CONCLUSION: Younger adults demonstrated greater attrition and may require more attention. We were unable to demonstrate differences in attrition among younger vs. older adolescents. Loss to follow-up was the main reason for attrition across all age groups. Overall, earlier presentation for ART care appears important for improved ART retention among adults.
Authors: Mweete D Nglazi; Katharina Kranzer; Pearl Holele; Richard Kaplan; Daniella Mark; Heather Jaspan; Stephen D Lawn; Robin Wood; Linda-Gail Bekker Journal: BMC Infect Dis Date: 2012-01-25 Impact factor: 3.090
Authors: Tsitsi Mutasa-Apollo; Ray W Shiraishi; Kudakwashe C Takarinda; Janet Dzangare; Owen Mugurungi; Joseph Murungu; Abu Abdul-Quader; Celia J I Woodfill Journal: PLoS One Date: 2014-01-29 Impact factor: 3.240
Authors: Kudakwashe C Takarinda; Anthony D Harries; Ray W Shiraishi; Tsitsi Mutasa-Apollo; Abu Abdul-Quader; Owen Mugurungi Journal: Int J Infect Dis Date: 2014-11-15 Impact factor: 3.623
Authors: C M McDonald; R Kupka; K P Manji; J Okuma; R J Bosch; S Aboud; R Kisenge; D Spiegelman; W W Fawzi; C P Duggan Journal: Eur J Clin Nutr Date: 2012-10-03 Impact factor: 4.016
Authors: Florian Vogt; Andrea M Rehman; Katharina Kranzer; Mary Nyathi; Johan Van Griensven; Mark Dixon; Wedu Ndebele; Hilary Gunguwo; Robert Colebunders; Mbongeni Ndlovu; Tsitsi Apollo; Rashida A Ferrand Journal: J Acquir Immune Defic Syndr Date: 2017-04-01 Impact factor: 3.731
Authors: Catrina Mugglin; Andreas D Haas; Joep J van Oosterhout; Malango Msukwa; Lyson Tenthani; Janne Estill; Matthias Egger; Olivia Keiser Journal: PLoS One Date: 2019-11-14 Impact factor: 3.240
Authors: Richard Makurumidze; Tsitsi Mutasa-Apollo; Tom Decroo; Regis C Choto; Kudakwashe C Takarinda; Janet Dzangare; Lutgarde Lynen; Wim Van Damme; James Hakim; Tapuwa Magure; Owen Mugurungi; Simbarashe Rusakaniko Journal: PLoS One Date: 2020-01-07 Impact factor: 3.240
Authors: J Chirenda; B Nhlema Simwaka; C Sandy; K Bodnar; S Corbin; P Desai; T Mapako; S Shamu; C Timire; E Antonio; A Makone; A Birikorang; T Mapuranga; M Ngwenya; T Masunda; M Dube; E Wandwalo; L Morrison; R Kaplan Journal: BMC Health Serv Res Date: 2021-03-18 Impact factor: 2.655